Clinical trial
TOTEM: Switch From Other Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to…
NCT00323492 · Gilead Sciences, Industry · Completed
Key facts
| NCT number | NCT00323492 |
|---|---|
| Title | TOTEM: Switch From Other Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to Once Daily Truvada |
| Official title | Open-label Randomized Multicenter Trial to Evaluate the Impact on the Lipid Profile of the Substitution of the NRTIs of a HAART Regimen by a Once Daily Fixed Dose Combination Tablet of Emtricitabine and Tenofovir DF Versus Maintained Treatment in HIV Infected Controlled Patients. |
| Acronym | TOTEM |
| Lead sponsor | Gilead Sciences, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Truvada, Current HAART regimen |
| Enrollment | 92 |
| Start date | Sep 1, 2005 |
| Primary completion | Jul 1, 2007 |
| Completion | Mar 1, 2008 |
| First posted | May 9, 2006 |
| Last update posted | Jan 20, 2010 |
| Countries | France |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: